Companies › Beijing QL Biopharmaceutical
3 active drug programs in 6 registered trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zovaglutide (ZT002 Injection) GLP-1 receptor agonist | GLP1R | Phase 3 | Overweight , Obesity; Overweight,Obesity; Overweight, Obesity | Dec 2026 |
| ZT006 GLP-1 receptor agonist | – | Phase 2 | Overweight , Obesity | Dec 2026 |
| ZT003 | – | Phase 1 | Healthy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07443059 | Zovaglutide (ZT002 Injection) | Phase 1 | Overweight , Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07550816 | Zovaglutide (ZT002 Injection) | Phase 1 | Overweight,Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07230132 | ZT006 | Phase 2 | Overweight , Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07184502 | ZT003 | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07697846 | Zovaglutide (ZT002 Injection) | Phase 1 | Overweight, Obesity | Metabolic and endocrine | Jan 2027 |
| NCT07230119 | Zovaglutide (ZT002 Injection) | Phase 3 | Overweight , Obesity | Metabolic and endocrine | May 2027 |
Shanghai Minwei Biotechnology Chendu DIAO Pharmaceutical Group Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Kailera Viking Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.